Fresenius SE & Co. KGaA (FRE) AI Stock Analysis

• Market Cap: €24.92B
• Dividend Yield: 2.05%
• Average Volume (3M): 750.62K
• Price to Earnings (P/E): 21.8
• Beta (1Y): 0.76
• Revenue Growth: 0.63%
• EPS Growth: N/A
• Country: DE
• Employees: 175,202
• Sector: General
• Sector Strength: N/A
• Industry: Medical - Care Facilities
• EPS (TTM): 0.78
• Shares Outstanding: 563,237,300
• 10 Day Avg. Volume: 787,875
• 30 Day Avg. Volume: 750,621
• PEG Ratio: 0.13
• Price to Book (P/B): 1.44
• Price to Sales (P/S): 1.21
• P/FCF Ratio: 23.03
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €56.40
• Price Target Upside: 26.77% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 10
• EPS Forecast (FY): 3.65
• Revenue Forecast (FY): €23.68B

• Rating: 51 Neutral
• Price Target: €44.00 ▼(-1.10% Downside)
• Action: Reiterated Date: 03/28/26
• Date: Action: Reiterated 03/28/26

The score is primarily held back by weak technicals (broadly below key moving averages with negative MACD). Financial performance is improving with better profitability and reduced leverage, but declining free cash flow and only moderate cash conversion limit confidence. Valuation is neutral with a moderate P/E and a modest dividend yield.

Positive Factors

Diversified recurring revenue

Fresenius operates complementary, recurring-revenue businesses (dialysis services/products via FMC and hospital pharmaceuticals via Kabi). This mix of treatment volumes plus contract-driven product sales supports durable, predictable revenue streams and reduces single-market cyclicality over months.

Negative Factors

Shrinking free cash flow

Two consecutive years of declining free cash flow and a moderate conversion ratio (~45% of net income) signal weaker cash-generation quality. That raises the likelihood of constrained discretionary spending, limits on shareholder returns, and greater sensitivity to higher capex or working-capital needs.

Fresenius SE & Co. KGaA Business Overview & Revenue Model

Company Description

Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. ...

Read more

Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. ...

How the Company Makes Money

Fresenius makes money through a portfolio of healthcare businesses that generate revenue from both recurring patient care/services and the sale of healthcare products. A major source of earnings is Fresenius Medical Care (FMC), which generates rev...

Read more

Fresenius makes money through a portfolio of healthcare businesses that generate revenue from both recurring patient care/services and the sale of healthcare products. A major source of earnings is Fresenius Medical Care (FMC), which generates rev...

Fresenius SE & Co. KGaA Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	22.87B	21.83B	21.07B	21.33B	37.08B
Gross Profit	5.69B	5.38B	4.97B	5.20B	9.81B
EBITDA	3.30B	3.04B	2.74B	2.65B	6.25B
Net Income	1.26B	471.00M	-594.00M	1.37B	1.82B
Balance Sheet
Total Assets	41.40B	43.55B	45.28B	76.42B	71.96B
Cash, Cash Equivalents and Short-Term Investments	1.58B	2.05B	2.56B	2.35B	2.75B
Total Debt	11.93B	13.58B	15.83B	27.76B	27.16B
Total Liabilities	21.63B	23.26B	25.63B	44.20B	42.67B
Stockholders Equity	19.10B	19.54B	19.00B	20.41B	19.00B
Cash Flow
Free Cash Flow	1.20B	1.52B	3.32B	2.28B	3.03B
Operating Cash Flow	2.69B	2.45B	4.46B	4.20B	5.08B
Investing Cash Flow	-942.00M	-510.00M	-3.19B	-2.61B	-2.82B
Financing Cash Flow	-2.42B	-2.18B	-1.38B	-1.60B	-1.45B

Fresenius SE & Co. KGaA Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 44.49
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:FRE, the sentiment is Neutral. The current price of 44.49 is below the 20-day moving average (MA) of 44.75, below the 50-day MA of 47.65, and below the 200-day MA of 46.88, indicating a bearish trend. The MACD of -1.00 indicates Negative momentum. The RSI at 44.07 is Neutral, neither overbought nor oversold. The STOCH value of 70.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DE:FRE.

Fresenius SE & Co. KGaA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DRW3	76 Outperform	€1.57B	9.32	9.11%	2.95%	2.14%	6.69%
MED	65 Neutral	€168.15M	6.90	10.71%	1.12%	4.90%	―
COP	60 Neutral	€1.43B	49.55	4.19%	0.20%	1.16%	-43.53%
FME	58 Neutral	€11.72B	12.14	7.26%	3.54%	2.10%	9.19%
RHK	57 Neutral	€830.04M	20.44	2.63%	0.77%	9.10%	-15.07%
Sector *	55 Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
FRE	51 Neutral	€24.92B	21.83	6.70%	2.05%	0.63%	―